BusinessCrinetics Pharmaceuticals Completes $63.5 Million Series B FinancingBy Nasdaq OMXMar 13, 2018, 6:00 PM UTC
BusinessCrinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018By Nasdaq OMXMar 12, 2018, 8:06 PM UTC
BusinessCrinetics Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care ConferenceBy Nasdaq OMXMar 7, 2018, 9:06 PM UTC
BusinessCrinetics Pharmaceuticals Appoints Marc Wilson as Chief Financial OfficerBy Nasdaq OMXJan 4, 2018, 2:01 PM UTC
BusinessCrinetics Pharmaceuticals to Present at J.P. Morgan Healthcare ConferenceBy Nasdaq OMXJan 2, 2018, 2:01 PM UTC
BusinessCrinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for AcromegalyBy Nasdaq OMXOct 26, 2017, 2:30 PM UTC
BusinessCrinetics Pharmaceuticals Awarded Two SBIR Grants to Develop New Therapeutics for Congenital Hyperinsulinism and Cushing’s DiseaseBy Nasdaq OMXSep 6, 2017, 1:01 PM UTC
